Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-blind, Placebo-controlled, Randomized, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-64264681 in Healthy Male and Female Subjects

Next Previous
Trial Profile

A Double-blind, Placebo-controlled, Randomized, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-64264681 in Healthy Male and Female Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Feb 2019

At a glance

  • Drugs JNJ 64264681 (Primary)
  • Indications Cancer; Immunological disorders
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Janssen Research & Development

    • Most Recent Events

    • 24 Jan 2019 Planned number of patients changed from 99 to 107.
    • 12 Aug 2018 Planned End Date changed from 20 May 2019 to 5 Aug 2019.
    • 12 Aug 2018 Planned primary completion date changed from 20 May 2019 to 5 Aug 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top